樂觀
$5.71
情境價格
$17.980
+0.151 (+0.84%)收盤時
Cryoport, Inc. is a provider of integrated, temperature-controlled supply chain solutions for the life sciences. The Company operates through two segments: segments: Life Sciences Services and Life Sciences Products. Its life sciences services include BioLogistics and BioStorage/BioServices, which provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Its life sciences products segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Its operating units include Cryoport Systems, CryoGene and MVE Biological Solutions (MVE). Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through transport, kit production, labeling, packaging, and others.
Cryoport Inc (CYRX) appears to be a good buy right now due to its current price of $17.98, which is below the average analyst price target of $19. Additionally, the stock has shown a strong year-to-date change of +88.08% and a recent 5-day change of +6.77%, indicating positive momentum. However, the main risk is its forward P/E ratio of 79.37, suggesting that the stock may be overvalued if earnings do not improve significantly in the near future.
Guggenheim
$19
2026-10-01
Guggenheim
2026-10-01
目標價
$19
Needham
$19
2026-08-07
Needham
2026-08-07
目標價
$19
Guggenheim
$16
2026-08-07
Guggenheim
2026-08-07
目標價
$16
Roth Capital
$21
2026-08-07
Roth Capital
2026-08-07
目標價
$21
BTIG
$25
2026-07-24
BTIG
2026-07-24
目標價
$25
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport Reports Strong Q1 2026 Earnings Growth

CRYOPORT Q1 REVENUE REACHES USD 47.8 MILLION, EXCEEDING IBES ESTIMATE OF USD 44.9 MILLION

CryoPort to Announce Q1 Earnings on May 4th

Cryoport to Announce Q1 2026 Financial Results on May 4
Cryoport, Inc. is a provider of integrated, temperature-controlled supply chain solutions for the life sciences. The Company operates through two segments: segments: Life Sciences Services and Life Sciences Products. Its life sciences services include BioLogistics and BioStorage/BioServices, which provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Its life sciences products segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Its operating units include Cryoport Systems, CryoGene and MVE Biological Solutions (MVE). Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through transport, kit production, labeling, packaging, and others. It operates in the Industrials sector (PHARMACEUTICAL PREPARATIONS industry).
Cryoport Inc (CYRX) appears to be a good buy right now due to its current price of $17.98, which is below the average analyst price target of $19. Additionally, the stock has shown a strong year-to-date change of +88.08% and a recent 5-day change of +6.77%, indicating positive momentum. However, the main risk is its forward P/E ratio of 79.37, suggesting that the stock may be overvalued if earnings do not improve significantly in the near future.
4 analysts cover CYRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。